WeedMD Reports Second Quarter 2018 Results

On Track for More Than 500,000 Square Feet in Cultivation by Year-End 2018, Positioning WeedMD as a Top Ten Licensed Producer by Production Capacity

Fully Funded with Strong Current Cash Position of $43 Million

Toronto, Canada, August 28, 2018 – WeedMD Inc. (TSX-V:WMD) (OTC:WDDMF) (FSE:4WE) (“WeedMD” or the “Company”), a federally-licensed producer and distributor of medical cannabis, is pleased to report its financial results for the three and six months ended June 30, 2018.

The Company reports revenues of $2.1 million for the quarter ending June 30, 2018, representing a quarter-over-quarter increase of 83% and a year-over-year increase of 787%. Revenue of $3.2 million in the first half of fiscal 2018 represents a 1271% increase compared to the first half of fiscal 2017.

“We are pleased with our performance in the quarter, with revenues growing in excess of 700% year-over-year,” said Keith Merker, CEO of WeedMD. “Having secured supply agreements with Shoppers Drug Mart, the Nova Scotia Liquor Corporation, the Alberta Gaming, Liquor & Cannabis Commission and the British Columbia Liquor Distribution Branch, we are well positioned to deliver on our milestones, including expanding production through our newly licensed greenhouse facility, additional provincial supply agreements, building market share and accelerating growth. Our production platform positions the Company to support existing and incoming supply commitments as well as pursue international distribution opportunities. With an expected 500,000 square feet of fully-funded production space online by the end of this year, WeedMD is poised to become a top ten licensed producer in terms of actual realizable production capacity.”

Financial Highlights:

For the three month period ended June 30 2018 2017
($) ($)
Revenue 2,089,163 235,659
Net Comprehensive Loss 1,763,007 4,759,845
Adjusted Operating Loss* 2,195,051 4,706,408
Cash Used from Operations 1,703,757 1,596,196
Loss per Share (Basic and Fully Diluted) 0.02 0.08
As at June 30, 2018 December 31, 2017
  ($) ($)
Cash and Cash Equivalents 39,503,944 24,692,678
Total Assets 73,766,029 39,605,187
Total Liabilities 6,949,209 14,472,639
Working Capital 43,500,124 25,713,807

*Adjusted Operating Loss is not a recognized measurement under IFRS and this data may not be comparable to data presented by other companies. Management believes Adjusted Operating Loss to be an important measure of the Company’s day-to-day operations, by excluding non-cash gains and losses and/or non-recurring items.

 

Corporate Highlights During and Subsequent to the Quarter ended June 30, 2018

  • Strathroy Greenhouse Update:
    • Licensing: Cultivation license was secured for WeedMD’s large-scale technologically advanced greenhouse in Strathroy, Ontario on June 8, 2018
    • Cultivation: Facility was commissioned and plants were moved into 25,000 square feet of recently licensed cultivation space throughout the month of June, placing the Company on schedule for its first harvest by September 2018
    • Immediate Expansion: Three grow rooms are currently in cultivation, with a fourth coming online over the next week. Six more rooms, representing a total of approximately 60,000 square feet, are expected to be licensed and populated with plants by the end of September
    • End of 2018 Goal: More than 400,000 further square feet are currently being retrofitted and are expected to be commissioned by the end of 2018, providing the Company with more than 500,000 square feet of total production space in cultivation

 

  • Fully Funded Greenhouse Expansion: With a current cash balance of $43 million, the Company’s expansion and business development plans are fully funded.
  •  

  • Shoppers Drug Mart Supply Agreement: Entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart, subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed distributor.
  •  

    • Provincial Government Supply Agreements: Entered into an agreement with the Alberta Gaming, Liquor & Cannabis Commission (“AGLC”), a memorandum of understanding with the British Columbia Liquor Distribution Branch (“BDLDB”), and a supply agreement with the Nova Scotia Liquor Corporation (“NSLC”) to supply each province with high-quality, branded cannabis products for the adult-use market. WeedMD is focused on nationwide distribution at optimal price points and remains in advanced discussions with various other provincial liquor boards and emerging private retail operators.

     

  • Strategic Partnership for Infused Beverages: Signed a definitive agreement with Phivida Holdings Inc., to develop and operate Cannabis Beverages Inc. (“CanBev”). Both companies will be strategic partners in the development of CanBev, and WeedMD will be the exclusive supplier of cannabinoid extracts to be used in cannabis infused consumer products.
  •  

  • Collaborative Research & Development: Entered into a research and development supply, and collaboration agreements, with Revive Therapeutics Ltd. (“Revive”), whereby WeedMD will supply Revive with cannabidiol (“CBD”) for the research program evaluating CBD in the treatment of liver disease, specifically non-alcoholic steatohepatitis (“NASH”) and autoimmune hepatitis (“AIH”).
  •  

  • Extracts Sales: From commissioning its extraction lab in January of this year, the Company is pleased to report that its unique cannabis oil products have been well-received by its customers and now represent approximately 13% of overall patient sales.
  •  

  • Building the Team: Keith Merker was appointed CEO of the Company, and Nichola Thompson as Interim CFO. The Company now employs over 100 people across a variety of disciplines, including production, sales, marketing, and finance, as it scales its operations.
  •  
    The Company’s financial statements and related management’s discussion and analysis for the period are available under the Company’s profile on SEDAR at www.sedar.com. All amounts are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards unless otherwise noted.

    About WeedMD Inc.

    WeedMD Inc. is the publicly-traded parent company of WeedMD Rx Inc., a federally-licensed producer and distributor of medical cannabis and oils under the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company operates a 26,000 sq. ft. indoor facility in Aylmer, Ontario, and a second cultivation site at its greenhouse facility located in Strathroy, Ontario, representing 610,000 sq. ft. or 14 acres under glass. WeedMD has entered into supply agreements in addition to strategic relationships with established cannabis brands. WeedMD is focused on providing medical cannabis to the seniors’ markets in Canada through its proprietary seniors care program. It is dedicated to educating healthcare practitioners and furthering public understanding of the role that medical cannabis plays – including as it pertains to regulatory requirements, indications and potential side effects.

    Follow WeedMD On:

       

    For further information, please contact:

    WeedMD Inc.

    Keith Merker, Chief Executive Officer
    Tel: 519-765-2440 Ext. 222
    Email: investor@weedmd.com

    To learn more, visit us at www.weedmd.com

    For Media Enquiries:

    Marianella delaBarrera
    Margin Communications & Public Relations
    Tel: 416-897-6644
    Email: marianella@marginpr.com

    Cautionary Statement on Forward-Looking Information

    This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon WeedMD’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.

    The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future growing capacity and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally; the ability of WeedMD to implement its business strategies; competition; crop failure; and other risks.

    Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, WeedMD does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for WeedMD to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in WeedMD’s Annual Information Form dated December 13, 2017 (the “AIF”) and other disclosure documents of WeedMD filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the AIF and other disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.

     


    NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE